DR info

臨床試験数 : 19 / 薬物数 : 36 - (DrugBank : 23) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

AF37702 Injection
   Takeda Development Centre Europe Ltd
      2006   Phase 2   EUCTR2005-004944-30-GB   Germany;United Kingdom;
      2006   Phase 2   EUCTR2005-004944-30-DE   Germany;United Kingdom;
AF37702, Hematide
   Takeda Development Centre Europe Ltd
      2006   Phase 2   EUCTR2005-004944-30-GB   Germany;United Kingdom;
      2006   Phase 2   EUCTR2005-004944-30-DE   Germany;United Kingdom;
Alemtuzumab
   University of Calgary
      2017   Phase 2   NCT03214354   Canada;
Allogeneic Bone Marrow Transplantation
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Anti-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Autologous Peripheral Blood Stem Cell Transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Bortezomib/dexamethasone
   Institute of Hematology & Blood Diseases Hospital
      2020   Phase 2   NCT04423367   China;
Campath, Chemo and/or TBI Allo SCT
   David Rizzieri, MD
      1999   Phase 2   NCT00004143   United States;
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Cyclophosphamide + pred
   Chulalongkorn University
      2009   Phase 3   NCT01288131   Thailand;
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Cyclosporine A
   Bing Han
      2020   Phase 4   NCT04470804   China;
Cyclosporine combine with mycophenolate mofetil
   Chulalongkorn University
      2009   Phase 3   NCT01288131   Thailand;
Daclizumab
   Neal Young, M.D.
      1999   Phase 2   NCT00001962   United States;
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Fludarabine Phosphate
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Hematide, peginesatide
   Takeda Development Centre Europe Ltd
      2006   Phase 2   EUCTR2005-004944-30-GB   Germany;United Kingdom;
      2006   Phase 2   EUCTR2005-004944-30-DE   Germany;United Kingdom;
Leucine
   Northwell Health
      2013   Phase 1/Phase 2   NCT01362595   United States;
Methotrexate
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Peginesatide
   Takeda
      2006   Phase 2   NCT00314795   France;Germany;United Kingdom;
Peripheral Blood Stem Cell Transplantation
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Rituximab
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00229619   United States;
Sirolimus
   Bing Han
      2020   Phase 4   NCT04470804   China;
      2018   Phase 4   NCT03364764   China;
   University of Calgary
      2017   Phase 2   NCT03214354   Canada;
Tacrolimus
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Peking Union Medical College Hospital
      2019   Phase 4   NCT03918265   China;
      2018   Phase 4   NCT03540472   China;
Treosulfan
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Trifluoperazine
   Adrianna Vlachos
      2019   Phase 1/Phase 2   NCT03966053   United States;